A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
Abroad (travel likely)CompletedPHASE1, PHASE2
Conditions
Muscular Dystrophy, Duchenne
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Study leads
Medical Director
Study Director
Sarepta Therapeutics, Inc.